Skip to content
Artwork for The Dime
BusinessEntrepreneurshipManagementScienceChemistry

The Dime

Bryan Fields

Most cannabis companies won't survive the next three years. The ones that do will have better capital discipline, sharper regulatory reads, and operational frameworks built for compression, not growth. The Dime is where cannabis operators, executives, and investors hear directly from the CEOs and founders making those decisions right now: MSO strategy, state-by-state market dynamics, cultivation and extraction economics, brand positioning, and the financing structures keeping companies alive. Bryan Fields hosts weekly conversations built for operators, not observers.

Play
  • 26 episodes
  • Avg 49 min
  • English
Counted on this page — what you have heard stays on this device, so it is not something the list can be paged by.
  • #312
    Tuesday · 47 min

    Throughput Is Not Profit, Ingredient-Based Manufacturing, and Fixing the Leak ft. Matt Erickson

    Throughput is the easiest extraction metric to celebrate and one of the easiest ways to hide a losing system. An operator can move more biomass while sacrificing recovery, product quality, margin, and the ability to respond when demand shifts. Matt Erickson argues that extraction should be designed around the business outcome, then separated into repeatable ingredient and formulation workflows that make costs, handoffs, and constraints visible. This week we sit down with Matt Erickson - Profi

  • #311
    November 6 · 56 min

    Europe's 51st State, EU GMP, and Building Before the Market Arrives ft. Michael Sassano

    The expensive decision rarely looks intelligent before the market needs it. Operators can build for the regulations in front of them, or for the direction regulators are already moving. Across global medical cannabis markets, internal labs, stability programs, EU GMP manufacturing, and control of distribution are beginning to separate companies that can scale profitably from those that can only trade product. This week we sit down with Michael Sassano - Europe's 51st state - Pharmaceutical di

  • #310
    October 26 · 44 min

    How AYRLOOM Built Its Advantage in New York Cannabis ft. Eddie Brennan

    A 115-year farm discovered that preserving the legacy meant letting a new crop compete with it. Ayrloom reached Beak & Skiff's revenue scale in three years, then forced the family to reallocate capital, people, land, and drying space while cannabis regulation kept the businesses legally separate. The advantage was not cannabis expertise. It was years of beverage manufacturing scars, retail-grade quality systems, and relationships strong enough to survive a crowded New York shelf. This week we

  • #309
    October 14 · 53 min

    Who Benefits From Federal Cannabis Limbo? ft. Jay Rosenthal

    Federal cannabis reform is supposed to open the same door for everyone. The current market says otherwise. The largest operators do not share one political agenda, and some of the barriers they complain about are also widening their moats. As capital markets, international medical standards, and state regulation collide, the operators built for uncertainty may be the ones hardest to dislodge. This week we sit down with Jay Rosenthal • Limbo as a moat • EU GMP advantage • Regulation's hidden wi

  • #308
    September 30 · 42 min

    What Makes Consumers Buy the Same Edible Again? ft. Kim Sanchez Rael

    Fast-acting edibles can command a premium, but labels such as "nano" do not prove the final product works. The larger operating question is whether the formulation improves taste, shelf stability, manufacturing efficiency, and trust at the same time. This week we sit down with Kim Sanchez Rael Fast onset economics The nano problem Science/ AI and so much more

  • #307
    September 16 · 48 min

    Europe Is Not a Rescue Plan ft. Jamie Pearson

    Jamie Pearson of New Holland Group joins Bryan Fields on The Dime to discuss European cannabis expansion, EU GMP standards, medical cannabis supply chains, and why operational discipline and market fit matter before entering international markets.

  • #306
    August 4 · 53 min

    Paige Figi: The Cannabis Industry Is Cheering A Ban On Medicine

    Much of the licensed cannabis industry is quietly counting the volume it expects to inherit from the federal hemp ban coming this November. \*\* Now December. What they may not realize is that the ban could eliminate the full-spectrum therapeutic hemp formulations that helped change America's view of cannabis and are used daily by an estimated 45 million Americans. The provision was written by two members of Congress, without a conference or regular order, and inserted into a massive spending

  • #305
    July 9 · 50 min

    Understand This Before You Use AI To Build Software ft. Chris Guthrie

    AI has made software easier than ever to build. That does not mean every internal tool should become the backbone of your business. In this episode, Bryan sits down with Chris Guthrie to break down the growing temptation inside cannabis companies to vibe code internal tools, dashboards, CRMs, ERPs, and operational systems in the name of saving money. The problem is not the first version. The problem is what happens two months later, when a field does not map, the workflow breaks, the person wh

  • #304
    June 25 · 1 hr 11 min

    Hirsh Jain: Rescheduling Is Already Picking Winners

    Cannabis rescheduling is not as simple as “Trump rescheduled cannabis.” States are interpreting rescheduling completely differently depending on their license structure. These tiny details are widening the gap between potential winners and losers. In this episode, we break down what actually changed, what is still unresolved, and why rescheduling may already be picking winners and losers. This week, we sit down with Hirsh Jain to discuss: • What the April order and June 29 hearing actually mean

  • #303
    June 22 · 41 min

    Germany Is the Engine: What BAT Knows That Cannabis Doesn't ft. James Yamanaka

    Predictable cash flow is the whole game. In cannabis, predictable is the one thing almost nobody has. Organigram CEO James Yamanaka came up over 20 years at British American Tobacco, where that discipline is the entire model. He thinks the opportunity starts there: trim the portfolio, stop chasing every trend, tighten the supply chain, lean on the science, and align operations. Germany's market could nearly double in the next two years, but capturing it will take more than expansion. This week

  • #302
    June 11 · 47 min

    Why Ohio Cannabis Is Built Different: Inside the Regulator-Operator Alignment That's Actually Working ft. Caroline Henry

    When a regulator asks what the downside is of adding one more testing requirement, what is the downside? Just a little more safe. Just in case. Especially when adding one more item to an already exhaustive testing panel. That logic is how licensed cannabis markets end up buried under compliance layers copied from other states, calibrated to someone else's problems. It is also exactly how two adjacent markets with nearly identical consumer bases, Ohio and Michigan, ended up with completely diff

  • #301
    May 21 · 50 min

    Cannabis Was Medicine. Now the Proof Is Catching Up, ft. Joel Stanley and Dr. Marcel Bonn-Miller

    The cannabis industry convinced the world it had a medicine before the science caught up. Now the science is here, and almost no one is paying attention. CBD is not a panacea. When Charlotte's Web opened hearts and minds, the messaging of what it could do ran years ahead of what the data could actually support. That gap created a backlash the legitimate medical thesis didn't deserve. What's left on the other side of the green rush is a near-complete forgetting of the reason this industry starte

  • #300
    May 15 · 43 min

    Joe Lustberg: What Cannabis Lenders See That Operators Miss

    The cash amount in your head and the cash you actually need are not the same number. That gap is where most cannabis businesses break. Joe Lustberg has financed operators across the country for years and watched that gap swallow businesses that looked fine on paper. He has also spent over two years paying rent on a Hamptons dispensary he cannot open because a municipality tried to rezone his property out from under him. The person telling you to build in 1.5X as your burn capital cushion has b

  • #299
    May 8 · 58 min

    The Hidden Margin Killer for MSOS ft. Braunz Muller

    Cannabis operators aren't short on data. They're drowning in it. The real problem is what happens when that data gets handed to the wrong person, read at the wrong time, or used to justify the wrong decision. Overproduction cycles, steep discounting, margin pressure building back into manufacturing: most of that traces back to data being used reactively instead of as a decision guidance tool. Layer on the reality of multi-state operations where every market runs a different system, tracks diffe

  • #298
    April 24 · 55 min

    Ed Rosenthal and Greg Baughman: You're Still Growing Cannabis Wrong

    A customer walks into the dispensary and asks the budtender for a flower recommendation. They end up with a degraded version of the once high-end flower that graced your cultivation floor. They do not know it. Your brand took the blame. Ed Rosenthal, the most referenced name in cannabis cultivation history, says the cannabis supply chain has a freshness problem that starts in the dry room and compounds at every handoff. The smell of your drying room that everyone loves walking into? Those are

  • #297
    April 6 · 40 min

    The Legal Market Was Never Built for Payments, Why Cannabis Still Breaks the Rules ft. Aubrey Amatelli

    The largest payment processor in the world handles cannabis in Canada. In the U.S., they will not touch it. That’s the gap. Aubrey Amatelli left JP Morgan believing that if you followed the rules, aligned with card brand requirements, and structured things correctly, you could build a compliant, stable payment product. Then came Mastercard shutdowns, a failed tech partner that cost six figures, and a stretch where 5,000 dispensaries lost payment access in a matter of weeks. What came out of tha

  • #296
    March 27 · 52 min

    Gretchen Gailey: Cannabis Industry Has No Idea How DC Works, Why Rescheduling Is Delayed

    Politics is a dirty business. Sometimes being feared is the influence you need because access is not the problem. Politicians say "we'll take care of this." Gretchen Gailey has a different approach: stab them in the back, push them down the stairs, and take credit for the fall. It's time to put fear behind cannabis. She spent 20 years on Capitol Hill. She's watched cannabis show up once a year for fly-ins, throw money at the wrong politicians, and wonder why nothing changes. This episode breaks

  • #295
    March 19 · 39 min

    15 Years of Cannabis Trading . Why I'll Sell Early (Unless This Happens) ft. Dan McDermitt

    Investing in cannabis requires a split personality. Everyone thinks they're early. Dan McDermitt has been trading the sector for 15 years — through the Canadian boom, the Biden promise, and the slow bleed that followed. His take: if you've been through multiple pump-and-dump cycles, you're not early anymore. You're just still here. This is a masterclass in separating trader psychology from fundamental conviction. Dan explains why he keeps a small position just to stay seated, why he already kn

  • #294
    March 13 · 50 min

    Premium vs Scale in Cannabis: Inside Rubicon’s Strategy ft. Margaret Brodie

    Most cannabis companies chased scale. Rubicon chased quality. What does it actually take to build a premium cannabis brand? Trust sits behind what “premium” really means, why consumers only give brands one chance, how Rubicon evaluates resource capacity and audits operations, and why Europe could become the next meaningful opportunity for their trusted brands. This week we sit down with Margaret Brodie, CEO of Rubicon Organics: • Why premium cannabis starts with flower• Consumers Trust• Inter

  • #293
    March 6 · 53 min

    Prop 64 Fine Print, Pesticide Drift, The Economics Behind Concentrates ft. Micah Anderson

    When California legalized cannabis, did anyone see 70% of the state opting out. Retail access never recovered. The illicit market stayed durable. And taxes kept compounding pressure on operators. Micah Anderson, CEO of LEEF Brands, explains how local bans strengthened the illicit market, why pesticide drift can wipe out millions in product, and why he is rebuilding a recovery and wellness push with NBA player Jimmy Butler. This week we sit down with Micah Anderson: Pesticide drift killing mill

Showing 1–20 of 26 episodes